[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100568871":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":32,"locations":38,"responsibleParty":60,"collaborators":62,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":67,"sex":73,"minAge":74,"maxAge":18,"enrollmentInfo":75,"targetDuration":18,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":41,"whyStopped":18,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Ibuprofen","EXPERIMENTAL","Ibuprofen tapering schedule during 3 weeks.",[13],"Drug: ibuprofen",{"label":15,"type":16,"description":17,"interventionNames":18},"Acetaminophen","NO_INTERVENTION","Acetaminophen or metamizole in case of allergy until pain resolution, according to routine clinical practice.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DRUG","ibuprofen","Ibuprofen tapering schedule during 3 weeks. First week: Ibuprofen 600 mg every 8 hours. Second week: Ibuprofen 600 mg every 12 hours. Third week: Ibuprofen 600 mg every 24 hours.",[9],[26,30],{"name":27,"affiliation":28,"role":29},"Fernando Domínguez-Rodriguez, MD, PhD","Heart Failure and Inherited Cardiac Diseases Unit, Department of Cardiology, Hospital Universitario Puerta de Hierro, IDIPHISA, Madrid, Spain","PRINCIPAL_INVESTIGATOR",{"name":31,"affiliation":28,"role":29},"Pablo García-Pavía, MD, PhD",[33],{"name":34,"role":35,"phone":36,"phoneExt":18,"email":37},"Fernando Domínguez Rodríguez, MD, PhD","CONTACT","+34 91 1916000","fdominguezr@salud.madrid.org",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Hospital Universitario Puerta de Hierro-Majadahonda","RECRUITING","Majadahonda","Madrid","28222","Spain","ES",{"type":48,"coordinates":49},"Point",[50,51],-3.87182,40.47353,{"lat":51,"lon":50},[54,55,58,59],{"name":34,"role":35,"phone":36,"phoneExt":18,"email":37},{"name":56,"role":35,"phone":18,"phoneExt":18,"email":57},"Noemí Ramos López","nramosl@cnic.es",{"name":27,"role":29,"phone":18,"phoneExt":18,"email":18},{"name":31,"role":29,"phone":18,"phoneExt":18,"email":18},{"type":61,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR",[63],{"name":64,"class":6},"Puerta de Hierro University Hospital","100568871","phase-3-non-steroidal-anti-inflammatory-drugs-in-acute-myocarditis-100568871",false,"NCT06686862","Non-Steroidal Anti-Inflammatory Drugs in Acute Myocarditis","Non-Steroidal Anti-Inflammatory Drugs Versus Conventional Treatment in Acute Myocarditis (INFLAMA Trial)","INFLAMA","Inclusion Criteria:\n\n* Aged 18 years or older.\n* Patients hospitalized for confirmed acute myocarditis and left ventricular ejection fraction ventricular \\>50%.\n* Elevated troponin I\u002FT (3 times above the upper limit of normal).\n* Absence of acute heart failure.\n* Absence of ischemic heart disease (ruled out by coronary angiography or coronary CT in individuals over 40 years).\n* Diagnostic criteria for myocarditis (Lake Louise, 2018 update) by cardiac magnetic resonance imaging.\n\nExclusion Criteria:\n\n* Kidney disease stage 3b, 4 and 5 (creatinine clearance by CKD-EPI \\\u003C45 ml\u002Fmin\u002F1.73 m2).\n* Severe liver failure (Child-Pugh class C).\n* Poorly controlled pharmacological hypertension (repeatedly systolic arterial pressure \\>140 mmHg).\n* Diagnosis criteria for acute pericarditis.\n* Moderate or severe pericardial effusion (\\>10 mm in total).\n* Hypersensitivity to NSAIDs or previous use in the last 7 days.\n* Contraindication for MRI.\n* Participation in another clinical trial.\n* Pregnancy, breastfeeding, or women of childbearing age unwilling to use appropriate contraception throughout the study.\n* Any circumstance that, in the investigator's opinion, compromises participation in the clinical trial.","ALL","18 Years",{"count":76,"type":77},150,"ESTIMATED","INTERVENTIONAL",[80],"PHASE3","Prospective, randomized, multicenter, open-label clinical trial to evaluate the safety and efficacy of a 3-week ibuprofen tapering regimen compared to conventional analgesic treatment (acetaminophen) in patients with acute myocarditis and left ventricular ejection fraction ≥50%. The objective is to assess the reduction in late gadolinium enhancement on cardiac magnetic resonance imaging at 6-month follow-up.",[83],"Myocarditis Acute",[85,86],"Nonsteroidal antiinflammatory agents","Magnetic Resonance Imaging","2026-02-12",{"date":89,"type":90},"2026-02-13","ACTUAL",{"date":92,"type":90},"2025-04-28",{"date":94,"type":77},"2027-10",{"name":5,"class":6},1]